



THE CANADIAN CANCER RESEARCH CONFERENCE | LA CONFÉRENCE CANADIENNE SUR LA RECHERCHE SUR LE CANCER



IN-PERSON PROGRAM

PROGRAMME DE LA

CONFÉRENCE EN PERSONNE

November 12 - 14, 2023

Halifax, NS

12 au 14 novembre 2023

Halifax, NS

ccra-acrc.ca/conference

CONFERENCE OVERVIEW – In Person

Sunday, November 12, 2023

8:00 am	Breakfast				
9:00 am	Welcome Remarks				
10:30 am	Plenary Session – Liquid Biopsies				
12:00 pm	Lunch and Poster Exhibit Session 12:20 – Pan-Canadian Cancer Data Strategy: Efforts to advance cancer data priorities <i>Canadian Partnership Against Cancer Sponsored Presentation</i> 1:00 – The Terry Fox Research Institute, Program Portfolio and Plans <i>Terry Fox Research Institute Sponsored Session</i>				
	Lightning Sessions				
1:30 pm	Bioinformatics, Big Data, AI and Technology	Survivorship	Immunotherapy	Cancer Clinical Research and Trials	Health Services Research, Health Economics, and Implementation Science
2:00 pm	Transition				
	Concurrent Sessions				
2:10 pm	Health Equity	Innovations in Clinical Trials	Pediatric oncology Targets, Testing, Trials and Transitions	Advances in Cancer Immunotherapy	WORKSHOP – DEI in Research Funding and Diversity in Science
3:40 pm	Break				
4:10 pm	Plenary Session – AI Across the Research Spectrum				

Monday, November 13, 2023

8:00 am	Breakfast					
	Concurrent Sessions					
9:00 am	Improving the Cancer Journey of First Nations, Inuit and Métis	Enhancing Palliative, End-of-Life, and Survivorship Experiences	Molecular Drivers of Cancer Metastases	Cancer Research from Atlantic Canada	WORKSHOP – AI Tools and Methods	
10:30 am	Transition					
	Lightning Sessions					
10:40 am	Metastasis	Screening, Early Detection, Diagnosis and Prognosis	Precision Medicine and Biomarkers	Health Disparities and Equity	Pediatric Cancer	
11:10 am	Break					
	Concurrent Sessions					
11:40 am	Adolescent and Young Adult Cancer	Tumour Microenvironment	Respecting Partnerships, Governance and Information for change in First Nations, Inuit and Métis cancer care	Crises Affecting Healthcare	Canadian Partnership for Tomorrow's Health: Canada's largest population laboratory for cancer research	Fireside Chat – Health Services and Policy Research
1:10 pm	Lunch and Poster Exhibit Session 1:30 – CCRA Open Meeting					
2:40 pm	Plenary Session – Clinical Innovations in the Real World					
4:10 pm	Break					
	Concurrent Sessions					
4:40 pm	The Gut Microbiome for Precision Oncology	Advances in Cancer Biology	Honoring Culture, Traditions and Language of First Nations, Inuit and Métis	Overcoming Treatment Resistance in Cancers	WORKSHOP – Patient Engagement	

Tuesday, November 14, 2023

6:15 am	Terry Fox Run				
8:00 am	Breakfast				
	Concurrent Sessions				
9:00 am	Reducing Your Risk of Cancer	Recent Advances in Cancer Treatment	Supporting First Nations, Inuit and Métis Cancer Strategies through Research	Networked Cancer Research in Canada	Multi-omics and Epigenetics
10:30 am	Transition				
	Lightning Sessions				
10:40 am	Metabolism	Patient Experience and Advocacy	Drug Discovery, Design, Delivery and Resistance	Genetics and Epigenetics	Cancer Risk and Primary Prevention
11:10 am	Break				
11:40 am	Plenary Session – Environment and Cancer				
1:10 pm	Closing Remarks				

*Scientific Program subject to change

APERÇU DU PROGRAMME – En Personne

Dimanche 12 novembre 2023

8 h	Déjeuner				
9 h	Mot de bienvenue				
10 h 30	Séance plénière – Les biopsies liquides				
12 h	Dîner et séance de présentations par affiches et d'exposition 12h20 - La stratégie pancanadienne de données sur le cancer : efforts visant à faire avancer les priorités en matière de données sur le cancer – Présentation parrainée par le Partenariat canadien contre le cancer 13 h - L'Institut de recherche Terry Fox : portefeuille de programmes et projets – Séance parrainée par l'Institut de recherche Terry Fox				
	Séances éclair				
13 h 30	La bio-informatique, les mégadonnées, l'IA et la technologie	La survie	L'immunothérapie	La recherche et les essais cliniques sur le cancer	La recherche sur les services de santé, l'économie de la santé et la science de la mise en œuvre
14 hr	Transition				
	Séances simultanées				
14 h 10	L'équité en santé	Les innovations dans les essais cliniques	L'oncologie pédiatrique : cibles, tests, essais et transitions	Progrès accomplis dans l'immunothérapie contre le cancer	ATELIER – L'EDI dans le financement de la recherche et la diversité en sciences
15 h 40	Pause				
16 h 10	Séance plénière – L'IA dans tous les domaines de la recherche				

Lundi 13 novembre 2023

8 hr	Déjeuner				
	Séances simultanées				
9 hr	Améliorer le parcours face au cancer des Premières Nations, des Inuits et des Métis	Améliorer les expériences des soins palliatifs, des soins de fin de vie et de la survie	Les mécanismes moléculaires à l'origine des métastases du cancer	Recherches sur le cancer provenant du Canada atlantique	ATELIER – Méthodes et outils liés à l'IA
10 h 30	Transition				
	Séances éclair				
10 h 40	Les métastases	Le dépistage, la détection précoce, le diagnostic et le pronostic	La médecine de précision et les biomarqueurs	Les disparités et l'équité en matière de santé	Les cancers pédiatriques
11 h 10	Pause				
	Séances simultanées				
11 h 40	Le cancer chez les adolescents et les jeunes adultes	Le micro-environnement tumoral	Respecter les partenariats, la gouvernance et l'information en faveur du changement dans les soins contre le cancer offerts aux Premières Nations, aux Inuits et aux Métis	Les crises touchant les soins de santé	Le Partenariat canadien pour la santé de demain : le plus grand laboratoire démographique du Canada pour la recherche sur le cancer
13 h 10	Dîner et séance de présentations par affiches et d'exposition 13 h 30 - Réunion ouverte de l'ACRC				
14 h 40	Séance plénière – Les innovations cliniques dans le monde réel				
16 h 10	Pause				
	Séances simultanées				
16 h 40	Le microbiome intestinal pour l'oncologie de précision	Progrès accomplis dans la biologie du cancer	Respecter la culture, les traditions et les langues des Premières Nations, des Inuits et des Métis	Surmonter la résistance au traitement des cancers	ATELIER – La participation des patients

Mardi 14 novembre 2023

6 h 15	La course Terry Fox				
8 h	Déjeuner				
	Séances simultanées				
9 h	Réduire votre risque de cancer	Les avancées récentes dans le traitement du cancer	Appuyer les stratégies de lutte contre le cancer chez les Premières Nations, les Inuits et les Métis grâce à la recherche	La recherche sur le cancer en réseau au Canada	La multiomique et l'épigénétique
10 h 30	Transition				
	Séances éclair				
10 h 40	Le métabolisme	L'expérience des patients et la défense de leurs intérêts	La découverte, la conception et l'administration des médicaments, et la résistance à ceux-ci	La génétique et l'épigénétique	Le risque de cancer et la prévention primaire
11 h 10	Pause				
11 h 40	Séance plénière – L'environnement et le cancer				
13 h 10	Mot de la fin				

* Programme sujet à changement

8:00 am

Breakfast

9:00 am

Welcome Remarks

Catherine Martin

Director Indigenous Engagement, Member of Millbrook Mi'kmaw community

Dr. Sara Urowitz

Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

Dr. Paula Robson

Alberta Health Services, Canadian Cancer Research Alliance

Dr. Helmut Hollenhorst

Nova Scotia Health Cancer Care Program, Dalhousie University

Dr. Jim Woodgett

Terry Fox Research Institute, Lunenfeld-Tanenbaum Research Institute

Dr. Sherri Christian

Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute

Dr. Robin Urquhart

Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority

10:30 am

Plenary Session – Liquid Biopsies

Chairs:

Dr. Sherri Christian

Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute

Ms. Melissa Coombs

Patient Partner

Predicting Response to Immune Checkpoint Therapy with Extracellular Vesicle Liquid Biopsy

The Clinical Utility of Liquid Biopsies in Lung Cancer

CHARMING Hereditary Cancer: Surveillance for Early Cancer using Cell-Free DNA Sequencing

Dr. Rodney Ouellette

Atlantic Cancer Research Institute

Sameena Khan

Princess Margaret Cancer Centre, University of Toronto

Dr. Trevor Pugh

Princess Margaret Cancer Centre, University of Toronto

12:00 pm

Lunch and Poster and Exhibit Session

12:20 – Pan-Canadian Cancer Data Strategy: Efforts to advance cancer data priorities *Canadian Partnership Against Cancer Sponsored Presentation*

1:00 – The Terry Fox Research Institute, Program Portfolio and Plans *Terry Fox Research Institute Sponsored Session*

Bioinformatics, Big Data, AI and Technology

Single-cell RNAseq identifies tumour stem-cell fate driven by lipid metabolism in liver cancer

Dr. Tallulah Andrews
University of Western Ontario

Exploring Cell Composition and Molecular Markers in Wilms Tumor for Improved Risk Stratification and Treatment

Mr. Fabian Bong
Dalhousie University

Developing the pan-Canadian Cancer Data Strategy (cancer data strategy) to guide cancer data improvements and implementation efforts

Ms. Natalie Fitzgerald
Canadian Partnership Against Cancer

Gaining insights into high risk AML through the integration of drug screening, RNA-seq, and Epigenetic Profiling

Miss Safia Safa-tahar-henni
IRIC/Université de Montréal

Automated tumour group classification from cancer electronic pathology reports using pre-trained language models

Dr. Jonathan Simkin
BC Cancer, Provincial Health Services Authority

ARS2 Association with subnuclear Paraspeckles: Implications for Hepatocellular Carcinoma Progression and Drug Resistance

Dr. Gobi Thillainadesan
Sunnybrook Research Institute

Privacy Risks of Machine Learning Models: Systematic Review and Meta-Analysis of Membership Inference Attacks and Implications for Data Security

Dr. Emily Walker
Cancer Care Alberta, Alberta Health Services

LncRNAs exhibit subtype-specific expression, survival associations, and cancer-promoting effects in breast cancer

Miss Marie-Claire Wasson
Dalhousie University

Survivorship

Virtually Supervised Exercise for People with Advanced Lung Cancer: Feasibility and Physical Function Results

Dr. Kristin Campbell
University of British Columbia

Missed Opportunities in Supporting Informal Cancer Caregiver (and Patient) Health

Mr. Thomas Christensen
Dalhousie University

Adherence to Breast Cancer Screening Guidelines and Risk of Breast Cancer-Specific Death

Dr. Rebecca Christensen
Dalla Lana School of Public Health

Development of a polygenic score to predict cisplatin-induced ototoxicity

Dr. Britt Drogemoller
University of Manitoba

Adjuvant Treatment in High-Grade Serous Endometrial Carcinoma: A Comprehensive Institutional Review

Dr. Sedighe Esmaeilzade
McGill University Health Center

Evaluating the association between pre-diagnostic routine lipid measurements and mortality among breast cancer survivors: A population-based retrospective cohort study

Miss Shana Kim
University of Toronto

Finding Intimacy Without Sex: Exploring the impact of lost intimacy and sexual function after cancer

Ms. Cecile Proctor
University of New Brunswick

Strategies to increase acceptance of referral to smoking cessation at an Ontario regional cancer centre

Dr. Deborah Saunders
Northeast Cancer Centre, Health Sciences North

Mental Health Status of Prostate Cancer Survivors in the Atlantic PATH Cohort

Dr. Ellen Sweeney
Dalhousie University

Immunotherapy

Combination immunotherapy with Smac mimetics potentiate cytokine-induced death of tumor cells

Dr. Shawn Beug
CHEO Research Institute

The role of the TME on combination temozolomide/nivolumab to treat glioblastoma revealed through computational modelling

Dr. Morgan Craig
Sainte-Justine University Hospital Research Centre, Université de Montréal

Exploring immune evasion in breast cancer using novel models of acquired resistance to PD-1/PD-L1 blockade

Dr. Kabir Khan
Sunnybrook Research Institute, University of Toronto

Augmenting Cancer Immunotherapy by Inhibition of the Fes Tyrosine Kinase

Mr. Brian Laight
Queen's University

Investigating VSV-based Oncolytic Virus to Overcome ICI-resistant Melanomas

Miss. Tiffany Lin
Goodman Cancer Institute, McGill University

Preclinical Mathematical Models for a Combined Treatment of Chemotherapy and Immunotherapy of Glioblastomas and Optimization of Advanced Treatments

Ms. Blanche Mongeon
Université de Montréal

The long, not short, of it: dual approaches for long-dsRNA based breast cancer therapies

Dr. Sarah Poynter
Wilfrid Laurier University

T cell-specific deletion of PRMT7 favors an immune active anti-tumoral microenvironment for melanoma

Dr. Nivine Srour
Lady Davis Institute, McGill University

Cancer Clinical Research and Trials

Comparative Effectiveness of Salvage Chemotherapy Regimens and Chimeric Antigen T-cell Receptor Therapies in Relapsed and Refractory Diffuse Large B Cell Lymphoma: A Network Meta-Analysis of Clinical Trials

Dr. Mahmood AminiLari
University Health Network

Anti-cancer immune response induced by cytokines

Dr. Alexandra Berger
Princess Margaret Cancer Centre

The untapped therapeutic potential of cholesterol-lowering drugs in solid tumors: the case of a cholesterol embargo on top of standard therapy in advanced pancreatic cancer NCT04862260

Dr. Anne Gangloff
Laval University

Ascites interleukin-10 levels and oncological outcomes in ovarian cancer

Dr. Gabriel Levin
Jewish General Hospital

Proteomics paves the way for personalized treatment of ductal carcinoma in situ: Analysis of tumor cores reveals proteomic and metabolic vulnerabilities and informs therapeutic strategies

Dr. Gerald Batist
Lady Davis Institute

Efficacy, effectiveness and immunogenicity of a reduced HPV vaccination schedule: a systematic review

Mr. Joshua Montroy
Public Health Agency of Canada

BOLD-100-001: A Phase 1b/2a Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Pre-Treated Advanced Gastrointestinal Cancers: Interim Safety Results

Mr. Malcolm Snow
Bold Therapeutics, Inc.

Shooting for the Moon: Can we cut cancer mortality by 50% by 2050?

Dr. Darren Brenner
University of Calgary

Lymphoma Diagnosis Pathway Implementation in Alberta

Mr. Tim Buckland
Alberta Health Services

The Cost of Cancer: A Societal View

Ms. Roxanne Garaszczuk
Canadian Partnership Against Cancer

Cancer in Canada 2023

Dr. Jennifer Gillis
Canadian Cancer Society

Pathways to cancer care after a suspected cancer diagnosis in the emergency department: A survey of emergency physicians across Ontario

Dr. Keerat Grewal
Sinai Health

Developing Authentic Relationships to Support Cancer Care System & Practice Change: A First Nations Methodology

Dr. Angeline Letendre
Canadian Indigenous Nurses Association

Cancer patients' attitudes toward delayed progression on imaging in the absence of improved survival

Lea Bill
Alberta First Nations Information Governance Centre and First Nations Advisor to CPAC

Estimating Cancer Diagnostic Interval Using Deep Learning Method based on Population-based Real-world Health Data

Dr. Andrew Robinson
Queen's University

Dr. Yuan Xu
University of Calgary

2:00 pm

Transition

2:10 pm

CONCURRENT SESSIONS

Health Equity

Chair:

Dr. David Busolo
University of New Brunswick, Faculty of Nursing, Moncton Campus, Beatrice Hunter Cancer Research Institute

Sundas Shamshad
Patient Partner

Prevention of Cervical Cancer in India through Self-Sampling (PCCIS)

Dr. Mandana Vahabi
Toronto Metropolitan University

Exploring primary care provider barriers and enablers to implementation of cancer screening with patients experiencing marginalization

Dr. Arlinda Ruco
St. Francis Xavier University

Disparities In Clinical Trial Enrolment At A Canadian Comprehensive Cancer Centre: A Fifteen-Year Retrospective Study

Dr. Gilla Shapiro
Princess Margaret Cancer Centre

Cancer incidence in people with intellectual or developmental disabilities: Two population-based retrospective cohort studies in Manitoba and Ontario, Canada

Dr. Alyson Mahar
Queen's University

Innovations in Clinical Trials

Chair:

Dr. Wendy Parulekar
Canadian Cancer Trials Group, Queen's University

David McMullen
Patient Partner

An Overview of Accelerated Clinical Trials (ACT) Canada

Implementation of the Canadian Remote Access Framework for Clinical Trials (CRAFT), a model for decentralized clinical trials (DCT)

Cost-Effectiveness Analysis of the Prostate Cancer Patient Empowerment Program (PC-PEP)

A phase IIb randomized placebo-controlled trial testing a long-chain omega-3 fatty acid MAG-EPA dietary supplement on prostate cancer aggressiveness

Dr. PJ Devereaux
McMaster University

Mr. Stephen Sundquist
3CTN - Canadian Cancer Clinical Trials Network

Ms. Alexandra Nuyens
Dalhousie University

Dr. Farah Ben Souilah
CHU de Québec - Université Laval

Pediatric Oncology Targets, Testing, Trials and Transitions

Chair:

Dr. Rebecca Deyell
Children's and Women's Health Centre of British Columbia

Adrienne Co-Dyre
Patient Partner

Large scale drug screens of human engineered acute leukemias and genetically matched patients

Defining and measuring the value of genetic testing from patients' perspectives: Developing the Patient-reported Genetic testing Utility InDEx (P-GUIDE) for oncology

Canadian innovation in pediatric hematology/oncology clinical trials: An update from the Canadian Pediatric Cancer Consortium (CPCC)

Transition to long-term follow-up care of AYA cancer survivors: multistakeholder perspectives

Dr. Brian Wilhelm
Université de Montréal

Dr. Robin Hajeems
The Hospital for Sick Children

Dr. Rebecca Deyell
Children's and Women's Health Centre of British Columbia

Dr. Katrin Julia Kaal
Nova Scotia Health, Dalhousie University

Advances in Cancer Immunotherapy

Chair:

Carol Pierre
Patient Partner

Dr. Tak Wah Mak
University of Toronto, Princess Margaret Cancer Centre

Metabolic and Neural Regulation of Immunity and Cancer

Investigating STING activation as a translational immunotherapy for soft tissue sarcomas

Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies

Dr. Tak Wah Mak
University of Toronto, Princess Margaret Cancer Centre

Ms. Karys Hildebrand
University of Calgary

Dr. Taha Azad
Université de Sherbrooke

WORKSHOP – DEI in Research Funding and Diversity in Science

Dr. Stephen Robbins
Lady Davis Institute for Medical Research, Jewish General Hospital

Dr. Juliet Daniel
McMaster University

Dr. Barbara Vanderhyden
Ottawa Hospital Research Institute

Dr. Kevin Hewitt
Dalhousie University

Dr. Christine Chambers
Dalhousie University

3:40 pm

Break

4:10 pm

Plenary Session – AI Across the Research Spectrum

Chairs:

Dr. Ali Bashashati
University of British Columbia, Vancouver Coastal Health Research Institute

Dr. Rosilene Kraft
Patient Partner

Ethics of AI in Radiology

Dr. Manisha Bahl
Mass General Research Institute, Harvard University

Dr. Muhammad Mamdani
Unity Health, St. Michael's Hospital, University of Toronto

Dr. John Lewis
Faculty of Medicine & Dentistry, University of Alberta

8:00 am

Breakfast

9:00 am

CONCURRENT SESSIONS

Improving the Cancer Journey of First Nations, Inuit and Métis

Chair:

Gail Turner

Canadian Partnership Against Cancer

A Qualitative Exploratory Study to Support the Elimination of Cervical Cancer in Canada's Indigenous Communities: Alberta Métis Settlement Perspectives

Dr. Angeline Letendre

Canadian Indigenous Nurses Association

The Giant Colon - Increasing Colorectal Cancer Screening Rates through Community Engagement: Manitoba

Mrs. Laryssa Sawchuck

CancerCare Manitoba

Courage, Compassion and Connection: exploring of the pre-diagnosis cancer journey for Labrador's Indigenous populations

Tracy Abraham

Interlake-Eastern Regional Health Authority

Dr. Jennifer Shea

Memorial University

Enhancing Palliative, End-of-Life, and Survivorship Experiences

Chair:

Dr. Harvey Chochinov

University of Manitoba

Sandra Dudych

Patient Partner

The impact of a cancer diagnosis on the short- and long-term income of cancer survivors in Canada

Dr. Stuart Peacock

Canadian Centre for Applied Research in Cancer Control (ARCC)

Knowledge products to support the knowledge translation of exercise recommendations for people with bone metastases: an experience-based co-design approach

Dr. Kelcey Bland

University of British Columbia

Edmonton Classification System for Cancer Pain: Comparison of Pain Classification Features and Pain Intensity across Diverse Palliative Care Settings in Canada

Dr. Mathieos Beylani

University of British Columbia

The Patient Dignity Question: Eliciting Personhood in Clinical Care

Dr. Harvey Chochinov

University of Manitoba

Molecular Drivers of Cancer Metastases

Chair:

Dr. Michael J. Monument

Department of Surgery, University of Calgary

Dr. Cara MacInnis

Patient Partner

From molecular mechanism to drug candidate, how we stop the vicious cycle of prolactin-accelerated breast cancer bone metastasis

Dr. Carrie Shemanko

University of Calgary

Identification and Functional Characterization of Novel Metastasis Driving Mutations from Gastroesophageal Adenocarcinoma

Mr. Ansley Gnanapragasam

McGill University

Genome-wide CRISPR screens identify a PIK3C3-mTORC1 signaling axis to target in metastatic breast cancer

Dr. Islam Elkholi

Lady Davis Institute for Medical Research, McGill University

Role of the lung microenvironment in mediating breast cancer metastasis: molecular cross-talk between The "seed" and the "soil"

Dr. Alison Allan

London Health Science Centre, Western University

Chair:

Dr. Jeannette Boudreau

Dalhousie University, Beatrice Hunter Cancer Research Institute

Barry Darby

Patient Partner

Memory Natural Killer Cell responses and their application in a cell-targeted cancer Immunotherapy

Mr. Daniel Medina-Luna

Dalhousie University

Revealing the hidden costs: Exploring the financial toxicity of hereditary cancer syndromes

Dr. Sepideh Rajeziessfahani

Memorial University

Investigating the Translational Potential of circPAX5 in B Cancer cells

Dr. Parinaz Nasri

Université de Moncton

Improving access to cancer screening is a collaborative endeavour: Perspectives of adult immigrants and refugees in New Brunswick

Dr. David Busolo

University of New Brunswick

WORKSHOP – AI Tools and Methods

Dr. Shirin Abbasinejad Enger

McGill University

Dr. Parsa Bagherzadeh

McGill University

Ms. Yujing Zou

McGill University

10:30 am

Transition

10:40 am

LIGHTNING SESSIONS

Metastasis

Investigation of roles of DNA methylation inhibition and STING agonist in the treatment of metastatic triple-negative breast cancer

Dr. Sofiane Berrazouane

Lady Davis Institute, McGill University

Overcoming Therapeutic Resistance by Targeting Ferroptosis in Cancer Cells Undergoing Anastasis

Miss Rachel Hausman

University of British Columbia, BC Cancer Research Centre

The Benefits and Limitations of dPCR in Detection of Minimal Residual Disease in Stage IV Colorectal Cancer

Dr. Lucyna Krzywon

McGill University Health Centre Research Institute

Trastuzumab and denosumab in the treatment of metastatic HER2-positive breast cancer: a case series and potential synergistic effect to explain their unusually long survival times

Mr. Rahman Ladak

Schulich School of Medicine and Dentistry, Western University

High Intratumoral Levels of Coco Leads to Vascular Dysfunction and Increased Tumor Aggressiveness

Mr. Kevin Lanthier

Maisonneuve-Rosemont Research Center

Exploring a link among protein synthesis, mitochondrial dysfunction, and epithelial-to-mesenchymal transition

Dr. Stephen Lewis

Atlantic Cancer Research Institute

Promotion of thrombin activatable fibrinolysis inhibitor (TAFI) activation in tumour microenvironment attenuates breast cancer metastasis in vivo

Ms. Tasnim Reza

University of Western Ontario

Counterbalance between Wnt/ β -catenin and ATF2-dependent signalling pathways drives cancer cell invasion and intravasation

Dr. Konstantin Stoletov

University of Alberta

The impact of verteporfin on lung metastasis in a mouse model of advanced osteosarcoma

Dr. Alicia Vilorio-Petit

University of Guelph

Screening, Early Detection, Diagnosis and Prognosis

Cancer Stem Cell Marker ALDH1A3 Mediates Invasion in Triple-Negative Breast Cancer by Inducing Plasminogen Activation

Dr. Alamelu Bharadwaj
Dalhousie University

Hospital-based personalized circulating tumor DNA tests for the identification of extremely good prognosis patients with residual Triple Negative Breast Cancer

Ms. Anna Klemantovich
Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital

DNA Organization Measurements from All the Individual Cells Within Tissue can be Highly Predictive of Cancer Cell Aggressiveness

Dr. Calum MacAulay
BC Cancer

Self-Collection for Cervix Screening in Never and Under-screened in the British Columbia, Organized Cervix Screening Population-Based Program: Preliminary Program Findings

Dr. Gina Ogilvie
UBC, Women's Health Research Institute

Is Canada prepared for Primary HPV-testing in Cervical Cancer Screening? A national study of the Knowledge, Attitudes, and Beliefs of Under and Adequately Screened Canadians

Dr. Samara Perez
McGill University Health Center

CervixCheck: Outcomes of a digital approach to self-collected cervical screening in a low-uptake region of British Columbia, Canada

Ms. Laurie Smith
BC Cancer and Women's Health Research Institute

Characterizing liquid biopsy signature in a chemotherapy resistant model of esophageal adenocarcinoma

Dr. Julia Burnier
McGill University

Making Progress in Cancer Control: The Number of Cancer Deaths Avoided in Canada

Dr. Matt Warkentin
University of Calgary

Precision Medicine and Biomarkers

Stool microbiome profiles in colorectal cancer: Establishment of lab protocols and preliminary results obtained from patients recruited to the Atlantic Cancer Consortium

Dr. Akinola Alafiatayo
Memorial University of Newfoundland

Tumor copy number alterations burden as a predictor for resistance to immune checkpoint blockade across different cancer types

Dr. Karama Asleh
Atlantic Cancer Research Institute

True bench-to-bedside science: An international pilot study modeling hard-to-cure pediatric cancers to prioritize therapeutic intervention

Miss Nadine Azzam
Children's Hospital of Eastern Ontario Research Institute

Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in HPV-associated head and neck cancer

Dr. Julia Burnier
McGill University

Exploring a novel triple therapy in hard-to-treat melanomas

Mr. Feiyang Cai
McGill University

Nanopore sequencing of advanced cancers identifies haplotype specific promoter methylation associated with clinically relevant HRD phenotype

Dr. Veronika Csizmok
Canada's Michael Smith Genome Sciences Centre at BC Cancer

Monitoring Epithelial Cell Subtypes in Whole Blood RNA of Prostate Cancer Patients: A Step Towards Precision Oncology

Miss Seta Derderian
RI-MUHC

KEAP1/NRF2 mutations in stem cells define an aggressive subset of head and neck cancer patients who have poor prognosis, lung metastasis and therapeutic failure

Dr. Syed Islam
King Faisal Specialist Hospital and Research Centre

Orthogonal methods independently quantify protein expression patterns associated with AKT inhibitor response in breast cancer cell lines and patient tumours

Ms. Constance Sobsey
McGill University

Health Disparities and Equity

In My Hands: Learnings from HPV-Based Self-Collection for Cervical Screening Approaches in Remote Indigenous Communities

Mrs. Katina Pollard
Métis Nation British Columbia

Differences in the colon cancer diagnostic interval by neighbourhood income

Ms. Laura Davis
McGill University

Patient-physician sex concordance and real-world disparities in cancer treatment practices and outcomes

Mr. Philip Ding
University of Alberta

Through the Lens of Health Equity: Organizational Barriers to Accessing Cancer Care for People who are Highly Marginalized

Dr. Tara Horrill
University of Manitoba

Responding to First Nations, Inuit and Métis Cancer Care Needs: Establishing & Working in Relationships to Address & Implement Culturally Safe Solutions

Dr. Angeline Letendre
Canadian Indigenous Nurses Association

Cancer Prevention & Screening Innovation

Dr. Angeline Letendre
Canadian Indigenous Nurses Association

Lea Bill
Alberta First Nations Information Governance Centre and First Nations Advisor to CPAC

Identifying best practices for engaging First Nations, Inuit, and Métis stakeholders in Patient and Family Advisory Committees

Ms. Alexandria McRorie
University of Calgary

Interventions designed to increase the uptake of lung cancer screening: an equity-oriented scoping review

Dr. Ambreen Sayani
Women's College Hospital

Advancing health equity within the pan-Canadian Cancer Data Strategy

Mrs. Kim Tran
Canadian Partnership Against Cancer

Pediatric Cancer

Impact of Early Phase Study Enrollment for Pediatric Oncology Patients on Symptom Burden and Quality of Life: Feasibility

Dr. Lesleigh S Abbott
CHEO

Alternative Polyadenylation in Noradrenergic to Mesenchymal Transition in Neuroblastoma

Ms. Rhea Ahluwalia
University of Toronto

Investigating the role of active beta-catenin (ABC) in promoting metastatic disease in pediatric osteosarcoma

Dr. Kristin Hinton
University of Alberta

Genome-wide CRISPR screening identifies the E3 ubiquitin ligase HERC1 as a driver of resistance to nucleoside analogs in acute myeloid leukemia

Mrs. Maja Jankovic
McGill University, Lady Davis Institute for Medical Research

Defining the cellular and molecular characteristics of relapsing Wilms Tumors using single-cell genomics

Dr. Tobias Karakach
Dalhousie University

CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax

Prof. Frederick A. Mallette
Université de Montréal, Maisonneuve-Rosemont Hospital Research Center

Exploring the Possible: 3CTN-C17 Initiatives Used as Incentives to Overcome Barriers to Clinical Trial Access for Pediatric Cancer Patients

Mr. James Schoales
Canadian Cancer Clinical Trials Network (3CTN)

Ms. Kathy Brodeur-Robb
C17 Council

Inferring parent-of-origin of germline variants in diverse hereditary cancer syndromes without parental data

Dr. Kasmintan Schrader
BC Cancer

Lmo2-induced T-cell acute lymphoblastic leukemia can switch addiction from initiating Lmo2/Lyl1 oncogenes to driving oncogenic Notch1

Dr. Cedric Tremblay
University of Manitoba

11:10 am

Break

11:40 am

CONCURRENT SESSIONS

Adolescent and Young Adult Cancer

Chair:

Dr. Uri Tabori
The Hospital for Sick Children

Sponsored by:



SickKids

Garron Family
Cancer Centre

Karen Haas
Patient Partner

CANON – The Canadian Adolescents and young adults NeuroOncology Network: From discovery to patient care

Dr. Uri Tabori
The Hospital for Sick Children

Developing a machine learning classifier for the diagnosis of Li-Fraumeni Syndrome

Ms. Brianne Laverty
The Hospital for Sick Children

Investigation of RAS-dependent and -independent functions of NF1: implications for targeted and immune therapies in melanoma

Dr. Ian Watson
McGill University

Tumour Microenvironment

Chair:

Dr. J. Patrick Murphy
Department of Biology, University of Prince Edward Island, Department of Pathology, University of Prince Edward Island, Beatrice Hunter Cancer Research Institute

Megan Emily Quintal
Patient Partner

Prognosis and chemoresistance in ovarian cancer: the role of immune marker expression

Dr. Arvind Mer
University of Ottawa

A new patient-derived organoid culture with adipocytes allows the identification of de novo resistant ER+ breast tumors to endocrine therapies

Dr. Afshin Raouf
University of Manitoba

Nuclear localization deficient IL-33 orchestrates a potent anti-tumorigenic microenvironment via the recruitment and programming of glioma inhibitory macrophage

Mr. Shyam Menon
Lady Davis Institute, McGill University

The role of ICAM1 in glioblastoma tumorigenesis under hypoxic conditions

Ms. Kaviya Devaraja
University of Toronto

Respecting Partnerships, Governance and Information for Change in First Nations, Inuit and Métis Cancer Care

Chair:

Ms. Emily Bear
University of Saskatchewan

Louise Bird
Patient Partner

The Need For, Development, and Implementation of the Indigenous Data Governance Matters process at Ontario Health

Mrs. Lisa Ellison
Ontario Health

The CINA Regional Initiatives Dashboard: Streamlining Cancer Research Collaboration

Mr. Oscar O'Neill
Canadian Indigenous Nurses Association

An environmental scan led by the Alberta First Nations Information Governance Centre (AFNIGC)

Angeline Letendre
Canadian Indigenous Nurses Association

Lea Bill
Alberta First Nations Information Governance Centre and First Nations Advisor to CPAC

Crises Affecting Healthcare

Chair:

Dr. Robin Urquhart

Jennifer Coish
Patient Partner

Models of Care to Support the Cancer Workforce

Red River Métis' barriers to access and health equities throughout a cancer journey: a qualitative study

Master the HHR Crisis through Innovation and Partnerships: Highlights of the Nova Scotia Health Cancer
Care Program Successes and Challenges

Dr. Craig Earle
Canadian Partnership Against Cancer

Ms. Chantal Perchotte
Manitoba Métis Federation

Dr. Helmut Hollenhorst
Nova Scotia Health Cancer Care Program,
Dalhousie University

Canadian Partnership for Tomorrow's Health: Canada's Largest Population Laboratory for Cancer Research

Chair:

Dr. Philip Awadalla
Ontario Institute for Cancer Research, University of Toronto, Ontario Health
Study, CanPath

Pauline McIntyre
Patient Partner

Risk factors for early-onset colorectal cancer: An analysis of Canadian prospective cohort studies

A Digital Health and Artificial Intelligence based Public Health Platform for Cancer Risk Prediction for
Population-Level Cancer Prevention

Changes in breast and cervical cancer screening during the COVID-19 pandemic: findings from Alberta's
Tomorrow Project

Harnessing data in the CARTaGENE Study in building prevention research program: from environmental
factors to biomarkers in cancer prevention

Dr. Dylan O'Sullivan
Alberta Health Services, University of Calgary

Dr. Samina Abidi
Dalhousie University

Dr. Sara Nejatnamini
Alberta Health Services

Dr. Vikki Ho
University of Montreal, University of Montreal
Hospital Research Centre (CRCHUM)

Fireside Chat -From Building Health Services and Policy Research into your Career to Building a Career in Health Services and Policy Research

Dr. Stuart Peacock
Canadian Centre for Applied Research in Cancer Control (ARCC)

Dr. Cynthia Kendall
Dalhousie University

Dr. Katrin Julia Kaal
Nova Scotia Health

Dr. Colleen Cuthbert
University of Calgary

Dr. Theresa Tsui
Hospital for Sick Children and University of Toronto

1:10 pm

Lunch and Poster and Exhibit Session

Sponsored by:



1:30 – CCRA Open Meeting

2:40 pm

Plenary Session – Clinical Innovations in the Real World

Chairs:

Dr. Sachin Katyal

Ms. Ruth Ackerman

Patient Partner

Multiple myeloma: a bench-to-bedside perspective with patients as partners

Dr. Tony Reiman

Beatrice Hunter Cancer Research Institute, Dalhousie University, University of New Brunswick

Understanding clonal evolution in recurrent medulloblastoma: In vivo modeling and cancer-selective drug discovery and design

Dr. Sheila Singh

Cancer Research Centre, McMaster University

Family Ties to Cancer: Innovative primary care strategies for hereditary cancer risk

Dr. June Carroll

Faculty of Medicine, University of Toronto, Granovsky Gluskin Family Medicine Centre, Sinai Health

4:10 pm

Break

4:40 pm

CONCURRENT SESSIONS

The Gut Microbiome for Precision Oncology

Chair:

Dr. Bertrand Routy

CHUM / CRCHUM

Darren Frew

Patient Partner

The rapid development of the gut microbiome as one of the hallmarks of cancer

Dr. Bertrand Routy

CHUM / CRCHUM

Distinct gut microbiome clusters in high-grade prostate cancer patients influence the antitumor efficacy of anti-PD-1 immunotherapy in mice

Mr. Jalal Laaraj

Centre de Recherche du CHU de Québec-Université Laval

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids

Mr. Jalal Laaraj

Centre de Recherche du CHU de Québec-Université Laval

Linking tumour, blood and oral microbiomes with cancer outcomes

Dr. Robyn Wright

Dalhousie University

Advances in Cancer Biology

Chair:

Dr. Paola Marcato

Department of Pathology, Dalhousie University

Dr. John K Mark

Patient Partner

Genome-Wide CRISPR Cas9 Screen Reveals a PARG - PTEN - Dependent Vulnerability in Melanoma

Mr. Emmanuel Asante

McGill University

Cataloguing and characterizing the chromosomes affected by genomic cataclysms in mantle cell lymphoma

Dr. Krysta Coyle

Simon Fraser University

Improving the cancer survivorship narrative by implanting artificial Intelligence along the health care continuum

Dr. Paola Marignani

Dalhousie University

Honoring Culture, Traditions and Language of First Nations, Inuit and Métis

Chair:

Talia Pfefferle

Canadian Partnership Against Cancer

National Indigenous Healthcare Provider Organization Response to First Nations, Inuit and Metis Cancer and Cancer Care Needs: Outcomes from a Cultural Safety Readiness Survey

Dr. Angeline Letendre
Canadian Indigenous Nurses Association

Mi'kmaq Birch Barch extract: a new potential treatment for cancer

Marilee Nowgesic
Canadian Indigenous Nurses Association

The Linguistic Indicators of Framing Tool: LIFTing harmful and deficit-based language out of cancer care and academic settings that involve Indigenous peoples

Dr. Stacey Ann Dmello Peters
Cape Breton University

Dr. Jessica Chan
University of British Columbia

Dr. Amy Shawanda
McGill University

Overcoming Treatment Resistance in Cancers

Chair:

Isabelle Allain
Patient Partner

Dr. Franco Vizeacoumar
Saskatchewan Cancer Agency, University of Saskatchewan

Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells

Dr. Grant Brown
University of Toronto

Targeting telomerase by synthetic dosage lethality

Mr. Vincent Maranda
University of Saskatchewan

Identifying cell cycle mediators as essential therapeutic vulnerabilities in cancers with non-V600 BRAF mutations

Dr. Melody Riaud
Lady Davis Institute

Bintrafusp alfa improves survival in ovarian cancer models by promoting T effector memory responses

Dr. Andrew Craig
Queen's University

WORKSHOP – Patient Engagement

Dr. Caroline Jose
Vitalité Health Network

Ms. Kimberly Badovinac
Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

Dr. Robin Urquhart
Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority

Dr. Ambreen Sayani
Women's College Hospital

Ms. Adrienne Co-Dyre
Patient Partner

6:15 am

Terry Fox Run

8:00 am

Breakfast

9:00 am

CONCURRENT SESSIONS

Reducing Your Risk of Cancer

Chair:

Shantelle Gould

Patient Partner

Dr. Rachel Murphy

BC Cancer Research Centre, University of British Columbia

You are what you eat but what if you are where you live?

There is kind of this awkward pressure that I should be doing it: Factors influencing youth vaping uptake

Exploring the Etiology of Rare Cancers Using a Large Occupational Cohort

The effectiveness and cost-effectiveness of population-level policies to reduce alcohol use: a systematic umbrella review

Dr. Rachel Murphy

BC Cancer Research Centre, University of British Columbia

Dr. Laura Struik

University of British Columbia

Dr. Paul Demers

Occupational Cancer Research Centre, Ontario Health

Ms. Umaima Abbas

University of Western Ontario

Recent Advances in Cancer Treatments

Chair:

Dr. Franco Vizeacoumar

Saskatchewan Cancer Agency, University of Saskatchewan

John Corriveau

Patient Partner

Unique transcriptome profile at the leading edge of tumours point to the therapeutic vulnerabilities

Investigation of novel anti-leukemic compounds uncovered through high-throughput screening of human model leukemias

EZH2 inhibition circumvents PRAME-mediated retinoid resistance in keratinocyte carcinomas

Targeting colorectal liver metastases with Alpha radiation emitting device - A pre-clinical study

Dr. Pinaki Bose

University of Calgary

Mrs. Karla Lucia Paez Martinez

Université de Montréal

Mr. Brandon Ramchatesingh

McGill University

Dr. Oran Zlotnik

McGill University Health Center Research Institute

Supporting First Nations, Inuit and Métis Cancer Strategies through Research

Chair:

Dr. Brenda Elias

University of Manitoba

Alberta Métis Cancer Strategy

Walking Together to Strengthen Indigenous Cancer Care in Alberta: Our North Star to Action

Miss Amanda Andrew

Métis Nation of Alberta

Mr. Chris Carriere

CancerCare Alberta

Ms. Catherine Dixon

Northwest Territories Health and Social Services Authority

Networked Cancer Research in Canada

Chair:

Dr. Sherri Christian

Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute

Wayne Olford

Patient Partner

Canadian Pediatric Cancer Consortium: Advancing Childhood Cancer Experience, Science and Survivorship

PRrecision Oncology For Young peopLE (PROFYLE): The pan-Canadian precision oncology program for children, adolescents and young adults with cancer

Terry Fox Research Institute, Marathon of Hope Cancer Centres Network

Using CanPath to study the earliest signatures of cancer development

Dr. Christine Williams

Ontario Institute for Cancer Research, Canadian Pediatric Cancer Consortium

Ms. Stephanie Grover

The Hospital for Sick Children, PRrecision Oncology For Young peopLE (PROFYLE)

Dr. Isabel Serrano

Terry Fox Research Institute, Marathon of Hope Cancer Centres Network

Dr. Philip Awadalla

Ontario Institute for Cancer Research, University of Toronto, Ontario Health Study, CanPath

Multi-omics and Epigenetics

Chair:

Dr. Touati Benoukraf

Memorial University of Newfoundland

Anita Hamilton

Patient Partner

Characterizing the Interplay of Multi-Omics Mechanisms in Cancers

Developmental epigenomic origins of Group 3 and 4 medulloblastoma

Defining functional metabolites in cancer by combining metabolomics and target engagement proteomics

Embracing complexity to achieve precision: multilayer cell fate control in cancer

Dr. Touati Benoukraf

Memorial University of Newfoundland

Dr. Shraddha Pai

Ontario Institute for Cancer Research

Dr. J. Patrick Murphy

University of Prince Edward Island

Dr. Hong Han

McMaster University

10:30 am

Transition

10:40 am

LIGHTNING SESSIONS

Metabolism

XP01/CRM1 inhibition modulates autophagy and protein metabolism in cancer cells

ALDH1A3 regulates key processes that required for breast cancer cell plasticity and progression

Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations

Fatty acid β -oxidation enzyme ECI1 drives aggressive prostate cancer phenotype and predicts poor clinical outcome

Delineating and targeting a novel metabolism-based post-translational mechanism regulating the abundance of the 'undruggable' oncoprotein c-MYC in medulloblastoma

The secret life of a Krebs Cycle enzyme in aggressive cancers and optic neuropathies

Mrs. Sophie Landry

Université de Moncton

Dr. Wasundara Fernando

Dalhousie University

Ms. Helgi Kuzmychova

University of Manitoba

Dr. Jacques Lapointe

McGill University

Emma Martell

University of Manitoba

Dr. Michael Moran

Hospital for Sick Children, University of Toronto

Patient Experience and Advocacy

Co-creation of a patient engagement strategy in cancer research funding

Ms. Suzanne Bays
Canadian Cancer Society

Prostatic Specific Antigen Screening and Prostate Biopsy Procedure Experiences for Men at Risk of Prostate Cancer: Preliminary Results of the Biomarkers and Prostate Cancer Prevention and Environment (BIOCaPPE) Study

Mr. Donald Wood
Canadian Cancer Society

Mrs. Farah Ben Souilah
CHU de Québec, Université Laval

Mental Health Among People Living With and Beyond Colorectal Cancer: A Patient-Oriented Constructivist Grounded Theory

Dr. Vicki Cheng
University of British Columbia

The Rethinking Clinical Trials (REaCT) program: transforming pragmatic, practice-changing, patient-centred research across Canada

Dr. Marie-France Savard
The Ottawa Hospital Research Institute

Ethical issues experienced in relationships between patients and other team members developing a strategy for meaningful patient engagement in cancer research funding

Dr. Jenny Leese
University of Ottawa

How do patients with hereditary cancer syndromes navigate the healthcare system? A qualitative comparative study across Canada

Ms. Brooklyn Sparkes
Memorial University of Newfoundland

Ethics as an enabler in co-design: Example of the Alberta Cancer Diagnosis Initiative

Dr. Fay Strohschein
University of Calgary, Alberta Health Services

Mise à l'échelle du programme PAROLE-Onco: Le partenariat de soins et de services au bénéfice des patients et de leurs proches touchés par le cancer pour améliorer leur expérience tout au long de la trajectoire de soins

Mrs. Cécile Vialaron
Centre de recherche du CHUM

Drug Discovery, Design, Delivery and Resistance

Spatiotemporal modelling of chemoresistance evolution in breast tumors uncovers key dependencies on SLC38A7 and SLC46A1

Dr. Yannick Audet-Delage
University of Ottawa

Best evidences for the existence of anti-cancer fibroblasts

Prof. Jean-Philippe Brosseau
Université de Sherbrooke

The Role of Ceramide Metabolism in Temozolomide Chemoresistance in Glioblastoma

Dr. Simone C. da Silva Rosa
University of Manitoba

Synergistic co-targeting of the thioredoxin and glutathione antioxidant systems in glioblastoma cells with aberrant EGFR expression

Dr. Elvis Martinez-Jaramillo
McGill University

Utilization of high-content imaging and bioactivity assays for drug screening of metallotherapeutic anticancer agents

Mr. Brian Park
Bold Therapeutics

Ex vivo testing of Ran GTPase inhibitors in human ovarian cancer samples via microfluidics models

Sabrina Ritch
CRCHUM

Genetics and Epigenetics

A systematic approach to studying the effect of cancer histone mutations

Dr. Maria Aristizabal

Targeting the histone methylation in cancer: the balance of H3K27 and H3K36 methylation

Dr. Dalia Barsyte-Lovejoy
University of Toronto

EZHIP, a new oncogene in osteosarcoma

Dr. Geoffroy Danieau
Research Institute of the McGill University
Health Centre

Hypermethylation and Silencing Associated With Poor Prognosis In HPV Positive Head and Neck Cancer

Ms. Fatemeh Farshadi
McGill University, Lady Davis institute

Understanding the Translational Landscape of High-Risk Basal Cell Carcinoma

Miss Sarah Ghezelbash
Lady Davis Institute, McGill University

The Functional Role of Chromosome 4p Loss in Triple Negative Breast Cancer

Miss Lynn Karam
Concordia University

Deciphering the role of epigenetic combination therapies in ovarian cancer

Mr. Marios Langke
McGill University

Regulation of TAZ expression by epigenetic modulators for the treatment of multiple myeloma

Dr. Aimee Wong
University of New Brunswick

Association between sleep characteristics and cancer survival: a Mendelian randomization study

Dr. Lin Yang
Alberta Health Services

Cancer Risk and Primary Prevention

Association between traffic-related air pollution and breast cancer risk in post-menopausal women in Alberta's Tomorrow Project

Ms. Mohadeseh Ahmadi
University of British Columbia

Oral co-infection with multiple alpha-human papillomavirus and head and neck cancer risk

Mary Amure
McGill University

Depression, Anxiety and the Risk of Cancer: An Individual-Participant Data Meta-Analysis

Mr. Yunsong Cui
Atlantic PATH, Dalhousie University

Examining the association between ambient exposure to nitrogen dioxide and breast cancer risk among high-risk Canadian women

Ms. Katherine Pullella
University of Toronto

The Nova Scotia Community Cancer Matrix (NS-Matrix): using small-area mapping of preventable cancers to inform and strengthen cancer prevention interventions

Dr. Nathalie Saint-Jacques
Nova Scotia Health

A "Sex Gap" in occupational lung cancer? Exploring sex-differences in lung cancer risk among Ontario workers

Dr. Jevana Sritharan
Ontario Health

Predicting the risk of high-risk colorectal adenomas with markers of glucose metabolism and liver function at the time of screening colonoscopy

Mr. R. Liam Sutherland
University of Sutherland

11:10 am

Break

11:40 am

Plenary Session – Environment and Cancer

Chairs:

Dr. Robin Urquhart

Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority

Dr. Don Desserud

Patient Partner

Indigenous-led Conversation and Environmental Wellness

Ms. Carol Crowe
Indigenous Visions Inc.

Lifetime radon exposure as a future lung cancer screening eligibility criterion in Canada: pilot study outcomes and upcoming clinical trial details

Dr. Aaron Goodarzi
Cumming School of Medicine, University of Calgary

Climate, Health & Sustainable Care

Dr. Fiona Miller
Centre for Sustainable Health Systems, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto

1:10 pm

Closing Remarks

Dr. Sara Urowitz
Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

Dr. Louisa Salemi

Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

Catherine Martin

Director Indigenous Engagement, Member of Millbrook Mi'kmaw community

***Scientific Program subject to change**

October 2023_v5